These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36380204)

  • 1. Nutrient-derived modification of mineral corticoid receptors is relevant to diabetic kidney disease progression.
    Kanasaki K
    Hypertens Res; 2023 Jan; 46(1):261-263. PubMed ID: 36380204
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspective on Nonsteroidal Mineralocorticoid Receptor Antagonism in Diabetic Kidney Disease.
    Ghuman JK; Tuttle KR
    Kidney360; 2022 Apr; 3(4):744-748. PubMed ID: 35721619
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification.
    Jo R; Shibata H; Kurihara I; Yokota K; Kobayashi S; Murai-Takeda A; Mitsuishi Y; Hayashi T; Nakamura T; Itoh H
    Hypertens Res; 2023 Jan; 46(1):19-31. PubMed ID: 36229526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PANEL DISCUSSION: DIABETES MELLITUS AND RELATED SUBJECTS].
    NAKAO K; NAKAYAMA M; HORIUCHI H; ODA M
    Naika; 1964 Apr; 13():733-46. PubMed ID: 14151354
    [No Abstract]   [Full Text] [Related]  

  • 5. [SIGNIFICANCE OF PITUITARY AND ADRENAL CORTEX HORMONES IN DIABETES MELLITUS].
    TAKEDA R; MIYAHO S; MORIMOTO S; HASUI K; KANEDA M; NAGANO T; YOKOYAMA T
    Nihon Rinsho; 1964 Apr; 22():835-44. PubMed ID: 14129792
    [No Abstract]   [Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy.
    Otomo H; Nara M; Kato S; Shimizu T; Suganuma Y; Sato T; Morii T; Yamada Y; Fujita H
    Metabolism; 2020 Dec; 113():154405. PubMed ID: 33069809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mineral-corticoid inhibition of renal inactivation of vasopressive substances].
    GUILLEMIN R; SELYE H
    Ann Endocrinol (Paris); 1950; 11(3):270-5. PubMed ID: 14811084
    [No Abstract]   [Full Text] [Related]  

  • 8. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease.
    Verma A; Patel AB
    Trends Endocrinol Metab; 2021 May; 32(5):261-263. PubMed ID: 33637415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.
    Piotrowski DW
    J Med Chem; 2012 Sep; 55(18):7957-66. PubMed ID: 22866979
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of O-linked N-acetylglucosamine modification in diabetic nephropathy.
    Gellai R; Hodrea J; Lenart L; Hosszu A; Koszegi S; Balogh D; Ver A; Banki NF; Fulop N; Molnar A; Wagner L; Vannay A; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1172-F1181. PubMed ID: 27029430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HYPOPHYSEO-ADRENAL FUNCTION IN DIABETIC ANGIOPATHY.
    SZUECS S; CSAPO G
    Acta Endocrinol (Copenh); 1964 May; 46():135-41. PubMed ID: 14175499
    [No Abstract]   [Full Text] [Related]  

  • 12.
    Akimoto Y; Yan K; Miura Y; Tsumoto H; Toda T; Fukutomi T; Sugahara D; Kudo A; Arai T; Chiba Y; Kaname S; Hart GW; Endo T; Kawakami H
    Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1359-F1374. PubMed ID: 31566433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
    Al Dhaybi O; Bakris GL
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():69-76. PubMed ID: 32267074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased glucocorticoid metabolism in diabetic kidney disease.
    Ackermann D; Vogt B; Bochud M; Burnier M; Martin PY; Paccaud F; Ehret G; Guessous I; Ponte B; Pruijm M; Pechère-Bertschi A; Jamin H; Klossner R; Dick B; Mohaupt MG; Gennari-Moser C
    PLoS One; 2022; 17(6):e0269920. PubMed ID: 35749380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced
    Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease.
    Stanton RC
    Semin Nephrol; 2021 Mar; 41(2):85-95. PubMed ID: 34140099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of purified glucagon (hyperglycemic-glycogenolytic factor, HGF) on carbohydrate and corticoid metabolism in normal and diabetic subjects.
    KIRTLEY WR; WAIFE SO; HELMER OM; PECK FB
    Diabetes; 1953; 2(5):345-9. PubMed ID: 13107530
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy.
    Sato A; Nishimoto M
    Hypertens Res; 2022 Aug; 45(8):1310-1321. PubMed ID: 35726084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A renaissance in the treatment of diabetic kidney disease, hypertension in chronic kidney disease, and beyond.
    Yahr J; Calle J; Taliercio JJ
    J Osteopath Med; 2021 Oct; 122(1):55-63. PubMed ID: 34648702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INSULIN BODIES & ANTIBODIES.
    ABELSON DM
    Med Sci; 1964 Aug; 15():42-8. PubMed ID: 14180801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.